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Abstract 
Objective  To investigate the role of oxidative stress, inflammation, hypercoagulability and neuroendocrine activation in the transition of 
hypertensive heart disease to heart failure with preserved ejection fraction (HFPEF). Methods  We performed echocardiography for 112 
patients (≥ 60 years old) with normal EF (18 controls and 94 with hypertension), and determined protein carbonylation (PC), and tetrahydrobiop-
terin (BH4), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), fibrinogen, plasminogen activator inhibitor type-I 
(PAI-I), von Willebrand factor, chromogranin A (cGA) and B-type natriuretic peptide (BNP) levels from their blood samples. Results  We 
found that 40% (38/94) of the patients with hypertension (HT) had no diastolic dysfunction (HTDD−), and 60% (56/94) had diastolic dysfunc-
tion (HTDD+). Compared to the controls, both patient groups had increased PC and BH4, TNF-α, PAI-I and BNP levels, while the HTDD+ 
group had elevated cGA and CRP levels. Decreased atrial and longitudinal left ventricular (LV) systolic and diastolic myocardial deformation 
(strain and strain rate) was demonstrated in both patient groups versus the control. Patients whose LV diastolic function deteriorated during the 
follow-up had elevated PC and IL-6 level compared to their own baseline values, and to the respective values of patients whose LV diastolic 
function remained unchanged. Oxidative stress, inflammation, BNP and PAI-I levels inversely correlated with LV systolic, diastolic and atrial 
function. Conclusions  In patients with HT and normal EF, the most common HFPEF precursor condition, oxidative stress and inflamma-
tion may be responsible for LV systolic, diastolic and atrial dysfunction, which are important determinants of the transition of HT to HFPEF. 
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1  Introduction  
Hypertension is the main underlying cause of heart fail-
ure with preserved ejection fraction (HFPEF). This condi-
tion partially or entirely accounts for 78% to 88% of HFPEF 
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cases.[1–3] The most common diseases causing HFPEF (hy-
pertension, diabetes mellitus, obesity and chronic renal dis-
ease) are associated with a proinflammatory, prothrombotic 
state and increased oxidative stress.[2] Proinflammatory cy-
tokines, such as interleukin-6 (IL-6) and tumor necrosis 
factor-α (TNF-α) are raised in HFPEF,[4] and predict future 
HFPEF development.[5] This proinflammatory state pro-
motes the activation, adhesion and subendothelial migration 
of circulating leukocytes in two ways: by increasing the 
expression of the vascular cell adhesion molecule (VCAM) 
and E-selectin, and by increasing the activity of nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase, 
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which leads to increased reactive oxygen species production 
in the coronary microvasculature endothelial cells.[2,6–8] The 
presence of nitrosative/oxidative stress was recently demon-
strated by using nitrotyrosine and dihydroethidium staining 
in cardiomyocytes of HFPEF patients. Nitrotyrosine stain-
ing reflects low nitric oxide (NO) bioavailability due to pe-
roxynitrite formation from NO by superoxide anion 
(O2−.).[6,9] 
Peripheral endothelial dysfunction was recently iden-
tified as an independent predictor of the outcome of HFPEF, 
thus suggesting a causal role of endothelial dysfunction in 
the pathogenesis of HFPEF.[10] In cardiomyocytes adjacent 
to dysfunctional endothelium, low NO bioavailability be-
cause of high nitrosative/oxidative stress decreases cyclic 
guanosine monophosphate (cGMP) production without al-
tering soluble guanylate cyclase activity. Low cGMP level 
accounts for low protein kinase G (PKG) activity in HFPEF 
myocardium, which results in hypertrophy and increased 
stiffness of the myocardium.[2,9,11] Both low cGMP content 
and low PKG activity were recently demonstrated in myo-
cardial homogenates of HFPEF patients.[9] 
Besides peripheral endothelial dysfunction, another im-
portant concept in the pathogenesis of HFPEF is oxidative 
stress due to myocardial nitric oxide synthase (NOS) un-
coupling. This myocardial NOS uncoupling is caused 
mainly by oxidative depletion of the NOS cofactor tetrahy-
drobiopterin (BH4).[12] In hypertonic animal HFPEF models, 
treatment with BH4 reversed left ventricular (LV) hypertro-
phy, fibrosis and diastolic dysfunction. However, this effect 
could not be observed when the animals were treated with 
an antihypertensive agent (hydralazine) or non-specific an-
tioxidants that do not affect NOS uncoupling (Tempol and 
tetrahydroneopterin). We can thus conclude that the above 
LV alterations (LV hypertrophy, fibrosis and diastolic dys-
function) were specifically due to oxidative stress resulting 
from myocardial NOS uncoupling and were not the results 
of hypertension or oxidative stress in general.[13,14] 
We hypothesized that oxidative stress and inflammation 
have an important (potentially primary) role in the patho-
genesis of LV diastolic and subtle systolic dysfunction in 
patients with hypertension and normal ejection fraction (EF), 
which is the most common precursor state of HFPEF. To 
this end, we investigated the presence of oxidative stress, a 
proinflammatory and prothrombotic state and endothelial 
dysfunction in patients with hypertension and normal EF. 
2  Methods 
The study was conducted from December 2007 to July 
2012 at the 3rd Department of Medicine, Semmelweis 
University, Budapest. We prospectively enrolled a total of 
112 patients ≥ 60 years old with normal LVEF (> 50%). 
Ninety-four participants were patients with uncomplicated 
hypertension and eighteen participants were age-matched 
normotensive, healthy controls. The average follow-up pe-
riod was 23.3 ± 12.5 months, depending on the time of en-
rollment. Forty-four of the patients were followed for three 
years, and each patient was followed for a minimum of one 
year. Annual follow-up examinations were set up, with each 
patient undergoing a physical examination, an electrocar-
diograph (ECG), a detailed echocardiography, a carotid 
ultrasound and a chest X-ray. Biochemical measurements 
were also performed. We used the same tests during the 
follow-up period and the baseline examinations.  
Note that measurements of BH4, total biopterin and 
B-type natriuretic peptide (BNP) were added to the study 
protocol only later. As a result, biopterin and BNP levels 
were measured in all patients at least once, BNP was meas-
ured twice in about 75% of the patients and three times in 
case of a few patients, while biopterin levels were measured 
twice only in a few patients.  
Seventeen patients did not finish the follow-up. Eight of 
them did not want to continue with the study, and nine pa-
tients satisfied one of the exclusion criteria (HFPEF deve-
loped in two of them). The study complied with the Decla-
ration of Helsinki and was approved by the Institutional 
Committee on Human Research. An informed consent was 
obtained from all patients. Hypertension was defined by a 
systolic blood pressure > 140 mmHg and/or a diastolic 
blood pressure > 90 mmHg, or by antihypertensive phar-
macotherapy. Blood pressure was measured three times 
according to the standard procedure, i.e., in a sitting position 
following a 10-min rest. Then the values were averaged. 
Exclusion criteria included diabetes mellitus, more than a 
mild degree valvular or congenital heart disease, the pre-
sence of electrical pacemakers or implantable cardiac defi-
brillators, prior cardiovascular surgery, an established his-
tory of coronary heart disease, prior or ongoing atrial tach-
yarrhythmias, prior or manifest heart failure, any malignant 
or immunological disease, anticoagulant or antioxidant 
treatment, or conditions associated with acute inflammation 
or stress. 
2.1  Biochemical measurements 
All measurements were carried out from plasma or serum 
samples. 
2.1.1  Oxidative stress parameters 
Protein carbonylation (PC) assays were based on the 
photometric method of Levine, et al.[15] 
Plasma BH4 levels were measured using high performance 
liquid chromatography (HPLC) based on the method of 
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Fukushima and Nixon[16] and modified by Fekkes and 
Voskuilen-Kooijman.[17] Briefly, blood was collected into  
4 mL Vacutainer tubes containing 7.2 mg K-EDTA and 0.1% 
(w/v) dithiothreitol (DTT) and centrifuged at 2650 r/min for 
20 min after standing at room temperature in the dark for 2 
to 3 h. Plasma was separated and frozen immediately at 
−80°C until analysis. The amount of BH4 was determined 
by the differential oxidation method of Fukushima and 
Nixon.[16] The BH4 level was calculated from the difference 
between total biopterin [BH4 plus 7,8-dihydrobiopterin 
(BH2) plus biopterin] level and the alkaline-stable oxidized 
biopterin level (BH2 plus biopterin). Total biopterin level 
was determined by acid iodine oxidation of BH2 and BH4 to 
biopterin and the alkaline-stable oxidized biopterin level 
was determined by using alkaline iodine, which oxidizes 
only BH2 to biopterin. 
2.1.2  Inflammatory parameters 
C-reactive protein (hs-CRP) concentrations were measured 
in serum samples with the ultrasensitive particle-enhanced 
immunoturbidimetric assay in Cobas Integra 800 analyzer 
(Roche, Basel, Switzerland). Interleukin-6 (IL-6) and tumor 
necrosis factor-α (TNF-α) levels were measured by high- 
sensitivity sandwich ELISA Kits (R&D Systems, Minnea-
polis, MN, USA), according to the instructions of the 
manufacturer. 
2.1.3  Coagulation parameters 
The von Willebrand factor antigen (VWF: Ag) level was 
measured by an in-house sandwich ELISA assay using rab-
bit polyclonal anti-human VWF antibodies (Dako, Glostrup, 
Denmark). Commercial reference plasma (Diagnostica 
Stago, Taverny, France) was used as calibration in each 
experiment. In addition, assay control samples (both pooled 
normal and commercially available plasma) were used in 
each experiment. 
Human tissue plasminogen activator inhibitor type I 
(PAI-I) concentrations were measured in citrated plasma 
samples with a commercially available ELISA kit according 
to manufacturer’s instructions (Hyphen BioMed, Neuville– 
Sur-Oise, France). 
Plasma fibrinogen was measured on an ACL TOP co-
agulation analyzer (Instrumentation Laboratory, Milano, 
Italy) using the prothrombin-derived method, according to 
the manufacturer’s instructions. 
2.1.4  Neuroendocrine parameters 
The chromogranin A (cGA) levels were determined by 
the commercially available chromogranin A assay (Cisbio 
Bioassays, IBA, Gif-sur-Yvette, France) according to manu-
facturer’s instructions. 
The concentration of the BNP levels were measured by 
immune fluorescence method using 250 μL EDTA-plasma 
(Triage BNP test, Biosite Diagnostics Incorporated, San 
Diego, CA, USA) as described in detail earlier.[18,19]  
2.2  Pulse wave velocity (PWV) measurement 
PWV was measured using the validated PulsePen tono-
meter (DiaTecne, Milan, Italy) with the patient in supine 
position as described earlier.[20,21] Briefly, two sequences of 
measurements were performed in each subject, and their 
mean was used for statistical analysis. The PulsePen device 
measures the time difference between the R wave of the ECG 
and the ‘foot’ of the pulse pressure wave, which was obtained 
sequentially above the carotid and the femoral arteries using a 
handheld tonometer, to calculate pulse transit time between 
these two sites. The average signal of at least 10 heart cycles 
was used in the measurements at both sites. Surface tape 
measurements were performed between the carotid site and 
the jugular notch, and between the jugular notch and the 
femoral site. The difference of these two distances was 
considered to be the pulse wave travel distance and this data 
was used to calculate PWV using PulsePen software. 
2.3  Carotid ultrasonography 
Echo-Doppler examination was performed using a Phi-
lips iE33 system (Philips Ultrasound, Bothell, WA, USA). 
The common, bulb, internal and external carotids of both 
left and right sides were studied in longitudinal and trans-
verse planes with anterior, lateral and posterior approaches. 
The carotid ultrasonography finding was scored as follows: 
score 0: absence of plaque and intima media thickness (IMT) 
< 1 mm; score 1: increased (≥ 1 mm) IMT; score 2: non- 
stenotic plaque (with or without increased IMT); and score 
3: stenotic (≥ 50% stenosis) plaque. 
2.4  Standard echocardiography 
Echocardiographic imaging was carried out using a Phi-
lips iE33 system (Philips Ultrasound, Bothell, WA, USA). 
Cardiac dimensions and wall thicknesses were measured 
from two-dimensionally guided M-mode tracings according 
to the recommendations of the American Society of Echo-
cardiography.[22] LV mass was computed by the Deve-
reux-modified cube formula.[23] Left atrial volume was cal-
culated using the biplane area-length method. The biplane 
Simpson method was applied to calculate LV end-diastolic 
and end-systolic volumes, stroke volume and LVEF. LV 
diastolic function was assessed using the combination of 
transmitral Doppler flow, pulmonary venous flow, iso-
volumic relaxation time (IVRT) and myocardial tissue 
Doppler septal early diastolic filling velocity (E’). LV dia- 
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stolic function was graded according to Nishimura and Ta-
jik:[24] Grade 1= impaired relaxation with normal filling 
pressure; Grade 1a = impaired relaxation pattern with in-
creased filling pressure; Grade 2 = pseudonormalized pat-
tern; and Grade 3 = restrictive pattern. Transmitral flow was 
acquired from the apical four-chamber view with the sample 
volume placed at the level of the tips of mitral leaflets. E/A 
ratio, E deceleration time, A wave duration and IVRT were 
determined. Pulmonary venous flow was acquired from the 
same apical four-chamber view by placing the sample vol-
ume within the right upper pulmonary vein. Peak systolic 
forward flow, diastolic forward flow, atrial reversal flow 
duration and peak velocity were measured from this trace. 
2.5  Color tissue Doppler imaging 
Real time color Doppler myocardial imaging data were 
obtained in the apical four-chamber, two-chamber and 
five-chamber views. Mitral annular velocities [peak systolic 
velocity, peak E’ and peak late diastolic (A’) velocities] 
were recorded from the lateral, septal, inferior, anterior, 
posterior, anteroseptal LV walls. The width of the image 
sector and the depth of the imaging were adjusted to achieve 
a frame rate more than 180 frames/s. Pulse repetition fre-
quency was set at the lowest possible level without aliasing. 
An insonation angle not exceeding 20o was maintained to 
ensure an appropriate alignment of the Doppler beam with 
the myocardial segment that was examined. Color-coded 
tissue Doppler images were also acquired over three con-
secutive cardiac cycles for each of the six LV walls and four 
atrial walls (in the apical four-chamber and two-chamber 
views from the mid lateral, inferior and anterior left atrial 
and mid lateral right atrial walls). We used narrow sector 
images (≤ 20o) with frame rates of 200–300 frames/s and the 
data were analyzed offline using the QLAB 6.0 advanced 
ultrasound quantification software (Koninklijke, Philips 
Electronics N.V. 2007). During the analysis, we measured 
the longitudinal LV peak systolic strain (S), end-systolic S, 
peak systolic, early diastolic and late diastolic strain rates 
(SR) in the basal and mid myocardial segments of the six 
LV walls in the apical views. The peak atrial contraction 
period, atrial reservoir period and atrial conduit period Ss 
and SRs were measured in the apical four- and two-chamber 
views from the mid lateral, inferior and anterior left atrial 
and the mid lateral right atrial myocardium. 
2.6  Statistical analysis 
All continuous data are expressed as mean ± SD unless 
otherwise stated. Categorical variables are expressed as 
proportions. Comparisons between two groups were per-
formed with two-tailed t test or two-tailed t test with 
Welch’s correction if variances were not equal according to 
the F test. Comparisons among groups used one-way analy-
sis of variance (ANOVA) followed by the Tukey’s multiple 
comparisons test for between-groups comparisons. The 
Kruskal–Wallis one-way analysis of variance by ranks was 
performed if Bartlett’s test indicated heterogeneity of vari-
ances and comparisons between groups used the two-tailed t 
test with Welch’s correction. Time series were compared 
using two-way ANOVA for repeated measures followed by 
the Bonferroni post-hoc test. Linear correlation coefficients 
were determined by calculating Pearson correlation. All 
tests were conducted at the two-sided 5% significance level. 
Statistical analysis was performed using GraphPad Prism5 
(GraphPad Software Inc., San Diego, CA, USA).  
3  Results 
3.1  Patient characteristics 
The control group and both patient groups (HTDD− and 
HTDD+) had similar gender distribution, height, weight, 
body surface area, diastolic blood pressure, heart rate, esti-
mated glomerular filtration rate values and hemoglobin 
concentration. No significant difference was found between 
patient groups in terms of medication (Table 1). There was 
no difference in age between the control group and the 
whole hypertensive patient group (66.1 ± 4.4 vs. 69.4 ± 7.7 
years, the data of the whole hypertensive patient group is  
not shown in Table 1) and between the control and the 
HTDD− group. 
However, patients in the HTDD+ group were slightly 
older than those in the control (P < 0.05) and HTDD− (P < 
0.01) groups. The body mass index (BMI) was higher in 
both patient groups than in the control group (P < 0.05 for 
HTDD− and P < 0.01 for HTDD+ groups). Serum 
creatinine levels were higher in the HTDD+ group than in 
the control group (P < 0.05). Compared to the control group, 
systolic blood pressure was similarly elevated in both pa-
tient groups (P < 0.01 for HTDD− and P < 0.001 for 
HTDD+ groups) (Table 1). 
3.2  LV diastolic dysfunction 
At the baseline examination, 40% (38/94) of the patients 
with hypertension and normal EF had no LV diastolic dys-
function (HTDD− group), and 60% (56/94) of the patients 
had mild, Grade 1 (54 patients) or Grade 1a (2 patients) LV 
diastolic dysfunction (HTDD+ group). 
3.3  LV systolic and atrial function 
Echocardiography results are summarized in Table 2. No  
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Table 1.  Patient characteristics. 
 
Controls  
(n = 18) 
HTDD−  
(n = 38) 
HTDD+ 
(n = 56) 
Age, yrs 66.1 ± 4.4 66.1 ± 5.6 71.6 ± 8.1*, ##
Sex, F/M 12/6 29/9 33/23 
Duration of HT, yrs 0 11.5 ± 11.6 14.4 ± 12.2
Height, cm 168.7 ± 8.4 164.3 ± 7.5 164.8 ± 8.6 
Weight, kg 70.1 ± 13.2 74.3 ± 18 80.2 ± 25 
BMI, kg/m2 24.6 ± 3.7 27.6 ± 5.8* 28 ± 4**, #
BSA, m2 1.8 ± 0.2 1.8 ± 0.2 1.8 ± 0.3 
Serum creatinine, μmol/L 71.6 ±14.8 70.3 ± 14.8 82.8 ± 25.2#
eGFR, mL/min 82.6 ± 19.9 88.4 ± 26.6 75.4 ± 27.1
SBP, mmHg 129.5 ± 16.6 146.5 ± 16.2** 148.9 ± 17.9**
DBP, mmHg 83.8 ± 9.1 85.9 ± 10.9 88.9 ± 10.8
Heart rate, beats/min 71.1 ± 8.3 74.9 ± 9.3 72.2 ± 8.0 
Hemoglobin concentration, g/L 140.9 ± 12.6 137.2 ± 13.1 138.9 ± 14.8
Medications (number of patients)   
BB 1 22 30 
ACEI 0 19 35 
ARB 0 9 13 
CCB 0 15 27 
Diuretics 0 22 35 
Aldosterone antagonists 0 0 0 
Platelet inhibitors 0 14 24 
Statin 3 13 29 
PPI 2 10 8 
*P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. HTDD− groups. 
ACEI: angiotensin convertase enzyme inhibitor; ARB: angiotensin receptor 
blocker; BB: beta-adrenergic receptor blocker; BMI: body mass index; BSA: 
body surface area; CCB: calcium channel antagonist; DBP: diastolic blood 
pressure; eGFR: estimated glomerular filtration rate; HT: hypertension; 
SBP: systolic blood pressure; PPI: proton pump inhibitor. 
 
significant between-groups differences were found either in 
traditional LV systolic function indices [2D-guided M-mode 
EF measurement using the LVIDd2−LVIDs2/LVIDd2 × 100 
formula (LVIDd: diastolic left ventricular internal dimen-
sion; LVIDs: systolic left ventricular internal dimension), 
EF Simpson, stroke volume (SV), LV outflow tract time 
velocity integral (LVOT-TVI), mitral annulus M-mode ex-
cursion] or in LV systolic function parameters based on 
myocardial velocity measurements by tissue Doppler imag-
ing (TDI) such as mitral annulus peak systolic velocity.  
However, the more sensitive myocardial deformation pa-
rameters (strain and strain rate) revealed LV systolic dys-
function in our patients with hypertension and normal EF. 
Compared to the control group, we found reduced absolute 
values for the following parameters in both patient groups: 
the mean peak longitudinal LV systolic S (P < 0.05 for both 
patient groups), systolic (P < 0.001 for both patient groups) 
and early diastolic SRs (P < 0.05 for HTDD− and P < 0.001 
for HTDD+ groups). In the HTDD+ group, the absolute  
Table 2.  Echocardiographic measurements. 
Parameter 
Controls  
(n = 18) 
HTDD− 
(n = 38) 
HTDD+  
(n = 56) 
2D guided M-mode EF, % 65.89 ± 7.99 66.21 ± 5.96 68.66 ± 8.17 
EF Simpson, % 67.61 ± 5.6 66.45 ± 4.8 64.53 ± 7.03 
Stroke volume, mL 71.4 ± 2 68.8 ± 17.9 63.7 ± 18.8 
ESV, mL 34.8 ± 12.4 34.7 ± 12.0 36.9 ± 14.6 
EDV, mL 106.2 ± 30.2 103.6 ± 28.2 101.7 ± 27.3 
LV outflow tract time  
velocity integral, cm 
23.75 ± 3.98 23.55 ± 2.91 23.55 ± 4.88 
Mitral annulus M-mode 
excursion, mm 
15.3 ± 2.3 15.05 ± 2.26 15 ± 2.11 
Mitral annulus peak sys- 
tolic velocity, cm/s 
8.44 ± 1.04 7.96 ± 1.06 8.12 ± 1.4 
LVM, g 166.2 ± 38 196.9 ± 77.6 226.4 ± 66.2**,#
LVM/BSA, g/m2 91.6 ± 14.9 106.56 ± 35.9* 122.7 ± 31**,# 
LVM/BMI, g × m2/kg 6.779 ± 1.218 7.255 ± 2.608 8.253 ± 2.287**
LAV, mL 59.3 ± 18.2 63.5 ± 21.2 65 ± 21 
LAV/BSA, mL/m2 32.7 ± 8.5 33.7 ± 9.5 35.5 ± 10.4 
LAV/BMI, mL × m2/kg 2.45 ± 0.785 2.32 ± 0.686 2.41 ± 0.829 
The mean of the longitu-
dinal LV peak strain, % 
−16.5 ± 3.0 −14.7 ± 2.7* −14.5 ± 2.0* 
The mean of the longitudi-
nal LV peak systolic SR, 1/s
−0.9 ± 0.14 −0.76 ± 0.16** −0.81 ± 0.12**, #
The mean of the longitudi-
nal LV peak early diastolic 
wave SR, 1/s 
1.12 ± 0.22 0.97 ± 0.2*,## 0.84 ± 0.16**,
Mean atrial contraction  
period SR, 1/s 
−2.89 ± 0.65 −2.4 ± 0.59* −2.45 ± 0.54* 
Mean atrial reservoir  
period SR, 1/s 
1.95 ± 0.39 1.53 ± 0.42** 1.55 ± 0.35**
*P < 0.05, **P < 0.01 vs. the control group; #P < 0.05, ##P < 0.01 vs. the 
HTDD− group. BMI: body mass index; BSA: body surface area; EDV: left 
ventricular end-diastolic volume; EF: ejection fraction; ESV: left ventricular 
end-systolic volume; LAV: left atrial volume; LV: left ventricle; LVM: left 
ventricular mass; SR: strain rate. 
 
value of the mean peak longitudinal LV systolic SR was 
increased (P < 0.05) and the longitudinal LV early diastolic 
SR was reduced (P < 0.01) compared to the HTDD− group. 
The absolute values of the mean peak atrial contraction 
period (P < 0.05 for both patient groups) and the atrial re-
servoir period (P < 0.001 for both patient groups) SRs were 
decreased in both patient groups compared to the control. 
3.4  Left atrial volume (LAV) and LV mass 
No differences were found between groups in terms of 
LAV, LAV indexed to body surface area (LAV/BSA) or 
LAV indexed to BMI (LAV/BMI). LV mass (LVM) in-
creased in the HTDD+ group compared to the control (P < 
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0.001) and HTDD− groups (P < 0.05), while LVM was 
similar in the HTDD− and the control groups. LVM/BSA 
increased (P < 0.05 for HTDD−, P < 0.001 for HTDD+ 
groups) in both patient groups versus the control, and in the 
HTDD+ group versus the HTDD− group (P < 0.05). LVM/ 
BMI increased (P < 0.01) in the HTDD+ group versus the 
control and in a borderline significant manner (P = 0.063) in 
the HTDD+ group versus the HTDD− group (see Table 2) 
[these LAV and LVM results will be published in another 
article written from this multipurpose study: (J Hypertens 
accepted for publication, 2014)]. 
3.5  Biochemical measurements 
Table 3 shows the biochemical measurement results. 
There was no significant difference in any of the investi-
gated biochemical parameters between the HTDD+ and 
HTDD− groups. 
Table 3.  Biochemical results. 
Parameter 
Control 
(n = 18) 
HTDD− 
(n = 38) 
HTDD+ 
(n = 56) 
PC, µmol/g 0.191 ± 0.131 0.306 ± 0.214* 0.29 ± 0.246* 
Plasma BH4, nmol/mL 0.917 ± 0.351 1.98 ± 2.1** 2.04 ± 1.99** 
Total biopterin,  
nmol/mL 
2.01 ± 0.86 3.05 ± 2.8 2.98 ± 2.46* 
CRP, mg/L 1.97 ± 1.67 2.91 ± 2.63 4.17 ± 4.21** 
IL-6, pg/mL 1.88 ± 1.04 2.4 ± 2.91 3.0 ± 4.49 
TNF-α, pg/mL 0.854 ± 0.778 1.75 ± 2.19* 2.26 ± 4.62* 
FIB, g/L 4.03 ± 0.61 4.46 ± 0.93 4.56 ± 0.95 
PAI-I, ng/mL 11.62 ± 5.44 21.11 ± 11.21** 21.23 ± 16.16**
VWF, Ag% 168.03 ± 57.59 148.27 ± 39.15 156.58 ± 48.93 
cGA, ng/mL 75.85 ± 17.3 136.04 ± 162.71 148.16 ± 166.34**
BNP, pg/mL 15.89 ± 9.24 29.8 ± 32.3* 43.49 ± 69.41**
*P < 0.05, **P < 0.01 vs. the control group. BH4: tetrahydrobiopterin; BNP: 
B-type natriuretic peptide; cGA: chromogranin A; CRP: C-reactive protein; 
FIB: fibrinogen; IL-6: interleukin-6; PAI-I: plasminogen activator inhibitor 
type I; PC: protein carbonylation; TNF-α: tumor necrosis factor- α; VWF: 
von Willebrand factor. 
 
3.5.1  Oxidative stress parameters 
Protein carbonylation (PC) (P < 0.05 for both) and 
plasma BH4 levels (P < 0.01 for both) increased in both 
patient groups. Plasma total biopterin level (BH4 + BH2 + 
biopterin) increased in the HTDD+ group (P < 0.05). 
3.5.2  Inflammatory parameters 
Only a non-significant increase in IL-6 levels could be 
detected in the patient groups. While TNF-α levels were 
increased in both patient groups (P < 0.05 for both), CRP 
level increased (P < 0.01) only in the HTDD+ group. 
3.5.3  Coagulation parameters 
There was no significant difference in fibrinogen and 
VWF: Ag levels. PAI-I levels increased (P < 0.001) in both 
patient groups. 
3.5.4  Neuroendocrine activation parameters 
BNP level increased in both patient groups (P < 0.05 for 
the HTDD− group, P < 0.01 for the HTDD+ group). cGA 
level increased only in the HTDD+ group (P < 0.01) and 
showed a non-significant elevation in the HTDD− group. 
3.6 The relation of LV diastolic function to the bio-
chemical parameters during follow-up 
During follow-up, we found no change in LV diastolic 
function in case of 89 patients. However, in case of 19 pa-
tients LV diastolic function deteriorated, and in case of four 
patients LV diastolic function improved with at least one 
grade. As the number of patients with improved LV dia-
stolic function was limited, the data was not sufficient for 
statistical analysis. In case of patients whose LV diastolic 
function deteriorated during the follow-up, we found in-
creased PC and IL-6 levels compared to the patients’ own 
baseline values (P < 0.01 for both PC and IL-6) and to the 
respective values of those patients whose LV diastolic func-
tion remained unchanged (P < 0.05 for IL-6; and at the time 
of the 3rd follow-up examination, P < 0.05 for PC) (Figure 1). 
During the follow-up, there was no difference in any other 
biochemical parameters between the two groups of patients 
whose LV diastolic function deteriorated and remained un-
changed. 
3.7  PWV and carotid score 
The PWV increased in the HTDD+ group compared to 
the control group (P < 0.05), indicating the presence of 
atherosclerosis in the great arteries (Figure 2). The PWV of 
both patient groups combined was also greater than that of 
the control group (P < 0.05). The carotid score was greater 
in the HTDD+ group versus both the control and the 
HTDD− groups (P < 0.05 for both) (Figure 2). 
3.8  Relevant correlations among the investigated pa-
rameters 
Table 4 highlights only the most important and relevant 
correlations. 
BH4 and PAI-I levels showed an inverse correlation with 
the absolute values of longitudinal LV systolic and early 
diastolic myocardial deformation parameters. 
The TNF-α and IL-6 levels also showed an inverse cor-
relation with the absolute values of longitudinal LV systolic 
myocardial deformation parameters. Similarly, IL-6 level  
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Figure 1.  Comparison of protein carbonylation and IL-6 levels during follow-up in patients whose LV diastolic function remained 
unchanged or deteriorated. *P < 0.05, **P < 0.01. The table includes the results of only those patients who had at least three measurements 
of the investigated parameters during the follow-up. BL: baseline; IL-6: interleukin-6; FU: follow-up; LV: left ventricular; PC: protein car-
bonylation.  
 
 
Figure 2. Pulse wave velocity and carotid score results. *P < 
0.05 versus the control group, #P < 0.05 versus the HTDD− group. 
HTDD−: hypertensive patients without left ventricular diastolic 
dysfunction; HTDD+: hypertensive patients with left ventricular 
diastolic dysfunction; PWV: pulse wave velocity. 
correlated inversely with the absolute values of longitudinal 
LV early diastolic myocardial deformation (SR). 
cGA levels showed a positive correlation with the atrial 
conduction time estimated from the [(P wave-LA contrac-
tion) − (P wave-right atrial contraction)] interval and the 
carotid score. Plasma BNP level showed a negative correla-
tion with the absolute values of atrial myocardial deforma-
tion parameters (Table 3) and with some more traditional 
parameters of LV systolic and diastolic function, such as  
mitral annulus M-mode excursion, mitral annulus peak sys-
tolic velocity, mean E’. Plasma BNP level also showed a 
negative correlation with some recently proposed parame-
ters of LV systolic dysfunction such as EF Simpson/LVM 
and EF Simpson/LVM/BSA.[25] Plasma BNP level showed 
a positive correlation with LAV, LAV/BSA, LVM/BSA 
and mean E/E’. 
Table 4.  The most relevant correlations. 
Correlated parameters P r 
BH4 with mean longitudinal LV peak S 0.02 0.251
With mean longitudinal LV peak systolic SR 0.002 0.329
With mean longitudinal LV peak early diastolic wave SR 0.008 −0.285
PAI-I with mean longitudinal LV peak S 0.014 0.232
With mean longitudinal LV peak early diastolic wave SR 0.009 −0.246
IL-6 with mean longitudinal LV peak S 0.008 0.249
With mean longitudinal LV peak early diastolic wave SR 0.009 −0.285
TNF-α with mean longitudinal LV peak S 0.025 0.213
cGA with (P wave-LAcontr int.) − (P wave-RAcontr int.) 0.026 0.22
With carotid score 0.018 0.254
BNP with mean atrial contraction period peak SR 0.004 0.274
With mean LA reservoir period peak S 0.016 −0.23
With mean LA reservoir period peak SR 0.004 −0.272
With mean mitral annulus M-mode peak excursion 0.036 −0.21
With mean mitral annulus peak systolic velocity < 0.001 −0.352
With mean E’ 0.001 −0.301
With mean E/E’ 0.022 0.218
With LVM/BSA 0.028 0.257
With EF Simpson/LVM 0.03 −0.207
With EF Simpson/LVM/BSA 0.013 −0.243
With LAV 0.001 0.309
With LAV/BSA < 0.001 0.35
PWV with BNP 0.035 0.239
With LVM 0.041 0.23
With EF Simpson 0.009 −0.294
With ESV 0.01 0.293
With mean longitudinal LV peak S < 0.001 0.535
With mean longitudinal LV peak systolic SR < 0.001 0.51
With mean longitudinal LV peak early diastolic wave SR < 0.001 −0.496
With mean atrial reservoir period peak S 0.012 −0.282
With mean atrial reservoir period peak SR < 0.001 −0.389
BH4: tetrahydrobiopterin; BNP: B-type natriuretic peptide; BSA: body 
surface area; cGA: chromogranin A; contr: contraction; E: transmitral flow 
peak early diastolic filling velocity; E’: mitral annular peak early diastolic 
filling velocity; EF: ejection fraction; ESV: left ventricular end-systolic 
volume; IL-6: interleukin-6; Int.: interval; LA: left atrium; LAV: left atrial 
volume; LV: left ventricle; LVM: left ventricular mass; PAI-I: plasminogen 
activator inhibitor type I; S: strain; SR: strain rate; RA: right atrium; TNF-α: 
tumor necrosis factor-α. 
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The PWV showed a strong inverse correlation with the 
absolute values of LV systolic and LV early diastolic myo-
cardial deformation parameters and with EF Simpson. The 
PWV showed a negative correlation with the mean atrial  
reservoir period peak S and SR and a positive correlation 
with ESV, LVM and BNP. 
4  Discussion 
4.1  LV dysfunction and transition to HFPEF are due 
to oxidative stress and inflammation in hypertension 
The increased PC and plasma BH4 levels in both patient 
groups versus the control group indicates the presence of 
oxidative stress in patients with hypertension and normal EF. 
The markedly increased PAI-I levels in both patient groups 
compared to the control group are consistent with the pres-
ence of increased oxidative stress, as it has been proved that 
PAI-I levels increase in parallel with oxidative stress.[26,27] 
There is some evidence that increased plasma BH4 levels 
are associated with decreased tissue BH4 levels leading to 
nitric oxide NOS uncoupling, and as a corollary, increased 
oxidative stress.[28,29] The increased TNF-α levels in both 
patient groups (HTDD+ and HTDD−) and the increased 
CRP level in the HTDD+ group compared with the control 
group verifies the presence of inflammation in our patients. 
Hypertension is the most common underlying cause and 
precursor condition of HFPEF. The transition of hyperten-
sive heart disease to HFPEF is characterized by progressive 
LV hypertrophy and the deterioration of LV diastolic and 
atrial functions.[30] Our results demonstrated that in patients 
whose LV diastolic function deteriorated during follow-up, 
PC and IL-6 levels increased compared to their own base-
line values and to those patients’ values whose LV diastolic 
function remained unchanged during follow-up. LVM in-
creased in line with the progressive LV diastolic dysfunc-
tion. Increased plasma BH4 levels have been shown to be 
associated with decreased endothelial and possibly with 
decreased tissue BH4 levels.[28,29] Thus, it is likely that the 
increased plasma BH4 levels in our patients can be associ-
ated with decreased NOS cofactor myocardial BH4 levels. 
This leads to myocardial NOS uncoupling and causes myo-
cardial oxidative stress. In hypertensive mouse HFPEF 
models,[13,14,31] it was elegantly shown that it is myocardial 
oxidative stress due to myocardial NOS uncoupling that is 
responsible for HFPEF, not oxidative stress in general or 
hypertension in itself. Thus, our results demonstrate that 
inflammation, oxidative stress and decreased tissue BH4 
levels–particularly myocardial oxidative stress due to myo-
cardial NOS uncoupling–promote unfavorable changes that 
might accelerate the transition of hypertensive heart disease 
to HFPEF. 
Plasma BH4, PAI-I, TNF-α and IL-6 levels showed an 
inverse correlation with the absolute values of longitudinal 
LV systolic and, with the exception of TNF-α, with the lon-
gitudinal early diastolic myocardial deformation parameters 
as well. This further reinforces the hypothesis that increased 
oxidative stress and inflammation may not only play a ma-
jor role in the deterioration of LV diastolic function, but 
may have a potential pathogenetic role in LV systolic dys-
function as well. 
4.2  Increased atherosclerosis in line with progressive 
LV diastolic dysfunction 
The increased PWV and the increased carotid score in 
the HTDD+ group versus the control and HTDD− groups 
indicate the presence of advanced atherosclerosis in the 
great arteries in line with the deterioration of LV diastolic 
function. Based on the evidence for a pathogenetic role of 
oxidative stress and inflammation in atherosclerosis,[32,33] it 
can be assumed that increased oxidative stress and inflam-
mation contribute to the transition of hypertensive heart 
disease to HFPEF and LV systolic and diastolic dysfunction 
in patients with hypertension, and at the same time result in 
increased atherosclerosis of great arteries. 
4.3  Possible causes of atrial dysfunction in patients 
with hypertension and normal EF 
Our findings that cGA levels increased in the HTDD+ 
group versus the controls, showed a positive correlation 
with the atrial conduction time, showed an inverse correla-
tion with the absolute values of atrial myocardial deforma-
tion parameters and a positive correlation with LA volume 
and LA volume/BSA, indicate that neuroendocrine activa-
tion occurring as a sequela of LV systolic and diastolic dys-
function may significantly contribute to the development of 
atrial dysfunction in hypertensive patients. Atrial dysfunc-
tion might be also an important determinant of the transition 
of hypertensive heart disease to HFPEF.[30] BNP levels cor-
relate inversely with some more traditional markers of LV 
systolic and diastolic dysfunction, and it suggests that neu-
roendocrine activation contributes to the deterioration of LV 
systolic and diastolic function in these patients. 
4.4  Clinical implications 
We believe that our results have significant clinical ap-
plications. To the best of our knowledge, currently there is 
no evidence-based treatment for HFPEF. In line with the 
results of other authors,[13,14,28,31] our findings also support 
the observation that administrating BH4 to inhibit myo-
cardial NOS uncoupling might prevent the underlying con-
Szelényi Z, et al. LV dysfunction in hypertension is due to oxidative stress 9 
  
http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology  
ditions from developing into HFPEF, or might be able to 
reverse manifestations of HFPEF.  
4.5  Limitations 
An important limitation of our study is that we were not 
in the position to perform biochemical measurements from 
myocardial samples for ethical reasons. Therefore, we could 
not measure myocardial BH4 levels and thus could not pro-
vide direct evidence for myocardial NOS uncoupling in our 
patients. Moreover, while at the start of the study none of 
our patients had HFPEF, during the follow-up only two pa-
tients developed this condition, which is a further limitation.  
Thus we could only verify that in case of patients with 
hypertension and normal EF (the most common precursor of 
HFPE) oxidative stress and inflammation can be linked to 
the deterioration of LV diastolic function, atrial dysfunction 
and progression of LV hypertrophy. All of these are impor-
tant determinants of the transition of hypertensive heart dis-
ease to HFPEF.  
As it was difficult to find ≥ 60-year-old healthy controls 
in a hospital environment who met all the selection criteria, 
the number of control patients was also relatively small.  
4.6  Conclusions 
Our results suggest that increased oxidative stress (par-
ticularly myocardial oxidative stress due to myocardial NOS 
uncoupling) and inflammation are not just epiphenomena in 
patients with hypertension and normal EF, but it is more 
likely that they play a pathogenetic role in subtle LV sys-
tolic dysfunction and deterioration of LV diastolic function 
and contribute to progressive atherosclerosis in the great 
arteries. Subtle LV systolic dysfunction and the deteriora-
tion of LV diastolic function are associated with progressive 
LV hypertrophy, neuroendocrine activation and atrial dys-
function, and all these factors are considered to be important 
determinants of the transition of hypertensive heart disease 
to HFPEF.  
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